Azimuth Capital Management’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q1 | $28M | Sell |
540,394
-1,808
| -0.3% | -$93.8K | 1.2% | 12 |
|
|
2021
Q4 | $32M | Sell |
542,202
-31,545
| -5% | -$1.56M | 1.29% | 7 |
|
|
2021
Q3 | $24.7M | Sell |
573,747
-2,794
| -0.5% | -$124K | 1.06% | 15 |
|
|
2021
Q2 | $22.6M | Buy |
576,541
+23,857
| +4% | +$928K | 0.98% | 18 |
|
|
2021
Q1 | $20M | Buy |
552,684
+8,445
| +2% | +$300K | 0.95% | 22 |
|
|
2020
Q4 | $20M | Sell |
544,239
-22,526
| -4% | -$826K | 0.99% | 23 |
|
|
2020
Q3 | $19.7M | Buy |
566,765
+2,790
| +0.5% | +$97.8K | 1.16% | 15 |
|
|
2020
Q2 | $17.5M | Buy |
563,975
+3,115
| +0.6% | +$106K | 1.11% | 19 |
|
|
2020
Q1 | $17.4M | Buy |
560,860
+5,183
| +0.9% | +$177K | 1.3% | 10 |
|
|
2019
Q4 | $20.7M | Sell |
555,677
-10,554
| -2% | -$376K | 1.26% | 8 |
|
|
2019
Q3 | $19.3M | Sell |
566,231
-13,894
| -2% | -$505K | 1.26% | 10 |
|
|
2019
Q2 | $23.8M | Sell |
580,125
-9,818
| -2% | -$390K | 1.58% | 6 |
|
|
2019
Q1 | $23.8M | Buy |
589,943
+2,031
| +0.3% | +$81.3K | 1.6% | 7 |
|
|
2018
Q4 | $24.3M | Sell |
587,912
-9,936
| -2% | -$412K | 1.86% | 4 |
|
|
2018
Q3 | $25M | Sell |
597,848
-7,127
| -1% | -$274K | 1.68% | 6 |
|
|
2018
Q2 | $20.8M | Sell |
604,975
-5,209
| -0.9% | -$178K | 1.5% | 8 |
|
|
2018
Q1 | $20.5M | Buy |
610,184
+18,469
| +3% | +$635K | 1.51% | 6 |
|
|
2017
Q4 | $20.3M | Sell |
591,715
-7,811
| -1% | -$266K | 1.47% | 7 |
|
|
2017
Q3 | $20.3M | Buy |
599,526
+73,049
| +14% | +$2.35M | 1.52% | 5 |
|
|
2017
Q2 | $16.8M | Sell |
526,477
-3,417
| -0.6% | -$108K | 1.32% | 9 |
|
|
2017
Q1 | $17.2M | Buy |
529,894
+6,667
| +1% | +$210K | 1.39% | 8 |
|
|
2016
Q4 | $16.1M | Buy |
523,227
+231
| +0% | +$7.05K | 1.38% | 9 |
|
|
2016
Q3 | $16.8M | Buy |
522,996
+6,515
| +1% | +$218K | 1.46% | 7 |
|
|
2016
Q2 | $17.3M | Sell |
516,481
-5,053
| -1% | -$161K | 1.54% | 7 |
|
|
2016
Q1 | $14.7M | Buy |
521,534
+18,656
| +4% | +$533K | 1.4% | 10 |
|
|
2015
Q4 | $15.4M | Buy |
502,878
+4,029
| +0.8% | +$127K | 1.5% | 9 |
|
|
2015
Q3 | $14.9M | Sell |
498,849
-9,565
| -2% | -$307K | 1.56% | 6 |
|
|
2015
Q2 | $16.2M | Buy |
508,414
+11,542
| +2% | +$376K | 1.57% | 7 |
|
|
2015
Q1 | $16.4M | Buy |
496,872
+22,537
| +5% | +$717K | 1.59% | 6 |
|
|
2014
Q4 | $14M | Buy |
474,335
+14,811
| +3% | +$425K | 1.44% | 8 |
|
|
2014
Q3 | $12.9M | Buy |
459,524
+1,202
| +0.3% | +$33.7K | 1.41% | 10 |
|
|
2014
Q2 | $12.9M | Buy |
458,322
+29,223
| +7% | +$833K | 1.44% | 10 |
|
|
2014
Q1 | $13.1M | Sell |
429,099
-25,251
| -6% | -$753K | 1.58% | 9 |
|
|
2013
Q4 | $13.2M | Buy |
454,350
+2,170
| +0.5% | +$63.2K | 1.57% | 9 |
|
|
2013
Q3 | $12.3M | Buy |
452,180
+168,673
| +59% | +$4.59M | 1.7% | 9 |
|
|
2013
Q2 | $7.53M | Buy |
+283,507
| New | +$7.83M | 1.33% | 11 |
|
Other funds holding PFE
Azimuth Capital Management's PFE Position: Q1 2022 in Review
Azimuth Capital Management reduced its Pfizer (PFE) stake by 0.33% in Q1 2022, selling an estimated $93.8K and leaving 540,394 shares worth $28M. The position accounts for 1.2% of the portfolio, ranked #12.
Azimuth Capital Management first reported a position in PFE in Q2 2013 and has held it in 36 quarters since. The position peaked at $32M in Q4 2021. 3,195 funds tracked by Wall St. Rank hold PFE as of Q1 2022.
- Azimuth Capital Management held 540,394 shares of Pfizer worth $28M as of Q1 2022.
- Azimuth Capital Management sold 1,808 Pfizer shares in Q1 2022, an estimated $93.8K.
- Pfizer made up 1.2% of Azimuth Capital Management's portfolio in Q1 2022, its #12 holding.
- Azimuth Capital Management first reported a position in Pfizer in Q2 2013 and has held it in 36 quarters since.
- Azimuth Capital Management's Pfizer position peaked at $32M in Q4 2021.
- 3,195 funds tracked by Wall St. Rank held Pfizer as of Q1 2022.
Based on Azimuth Capital Management's 13F filing for Q1 2022, filed 13 May 2022.